El SalvadorTuberculosis profile
Population  2016 6.3 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.077 (0.047–0.11) 1.2 (0.74–1.8)
Mortality (HIV+TB only) 0.053 (0.037–0.072) 0.84 (0.59–1.1)
Incidence  (includes HIV+TB) 3.8 (2.9–4.8) 60 (46–76)
Incidence (HIV+TB only) 0.26 (0.17–0.37) 4.1 (2.6–5.8)
Incidence (MDR/RR-TB)** 0.14 (0.076–0.21) 2.2 (1.2–3.3)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.21 (0.16–0.26) 1 (0.76–1.3) 1.2 (0.92–1.5)
Males 0.24 (0.18–0.3) 2.3 (1.7–2.9) 2.6 (1.9–3.2)
Total 0.45 (0.33–0.56) 3.3 (2.5–4.2) 3.8 (2.9–4.8)
TB case notifications, 2016  
Total cases notified 3 050
Total new and relapse 3 034
          - % tested with rapid diagnostics at time of diagnosis 12%
          - % with known HIV status 98%
          - % pulmonary 87%
          - % bacteriologically confirmed among pulmonary 90%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 80% (63–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.04 (0.02–0.05)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 201 7%
          - on antiretroviral therapy 193 96%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  79
(40–120)
Estimated % of TB cases with MDR/RR-TB 2.9% (1.4–4.5) 4.1% (1.3–9.2)  
% notified tested for rifampicin resistance 49% 35% 1 460
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 7, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 6, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 92% 2 452
Previously treated cases, excluding relapse, registered in 2015 56% 9
HIV-positive TB cases registered in 2015 74% 182
MDR/RR-TB cases started on second-line treatment in 2014 73% 15
XDR-TB cases started on second-line treatment in 2014   0
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
10% (9.4–11)
TB financing, 2017  
National TB budget (US$ millions) 5.9
Funding source: 24% domestic, 76% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-11-17 Data: www.who.int/tb/data